• Part IA
• Chapter 1. Epidemiology of Autism Spectrum Disorders
• Chapter 2. TBD
• Chapter 3. Pediatric and Neurological Assessments
• Chapter 4. Gender Dysphoria, Gender Incongruence, and Sexual Identity
• Chapter 5. Racial and Ethnic Disparities in Assessment and Evaluation of Autism Spectrum Disorder
• Chapter 6. Digital Biomarkers in Diagnostics and Monitoring of Autism Spectrum Disorders
• Part IB
• Chapter 7. Social Communication
• Chapter 8. Restricted and Repetitive Behaviors
• Chapter 9. Diet and Nutrition
• Part IIA
• Chapter 10. Genetics and Genomics of Autism
• Chapter 11. Epigenomics
• Chapter 12. Prenatal, Perinatal, and Parental Risk Factors
• Chapter 13. Animal Models of Autism Spectrum Disorders
• Chapter 14. Electrophysiological Studies Across ASDs
• Chapter 15. Environmental Toxicity and Immune Dysregulation
• Part IIB
• Chapter 16. Overview of Syndromic Causes of Autism and Commonalities in Neurobiological Pathways
• Chapter 17. Fragile X Syndrome and Associated Disorders
• Chapter 18. Tuberous Sclerosis Complex
• Chapter 19. 16p11.2 and Other Recurrent Copy Number Variants Associated With Autism Susceptibility
• Chapter 20. Rett Syndrome
• Chapter 21. Prader-Willi Syndrome
• Part IIC
• Chapter 22. Neuroanatomical Findings in Autism Spectrum Disorders
• Chapter 23. The Amygdala in Autism Spectrum Disorders
• Chapter 24. Neurobiology of ASD Informed by Structural Imaging Research
• Chapter 25. Positron Emission Tomography
• Chapter 26. Functional Magnetic Resonance Imaging
• Part IIIA
• Chapter 27. Serotonergic Medication in Autism Spectrum Disorder (ASD)
• Chapter 28. Antipsychotics
• Chapter 29. Treating Hyperactivity in Children With Pervasive Developmental Disorders
• Part IIIB
• Chapter 30. Complementary and Integrative Approaches
• Chapter 31. Experimental Therapeutics: Oxytocin
• Chapter 32. Vasopressin
• Chapter 33. N-Acetylcysteine
• Chapter 34. Arbaclofen: From Animal Models to Clinical Trials in Autism
• Chapter 35. Cannabis, Cannabinoids, and Immunomodulatory Agents
• Part IIIC
• Chapter 36. Behavioral Treatments for Autism Spectrum Disorder
• Chapter 37. Early Start Denver Model
• Chapter 38. The Developmental, Individual Difference, Relationship-Based Intervention Model: A Comprehensive Parent-Mediated Approach
• Chapter 39. Autism Interventions in Schools Mediated by Teachers, Paraprofessionals, and Peers
• Chapter 40. Language and Communication Challenges and Treatments in Autism Spectrum Disorder
• Part IIID
• Chapter 41. Transcranial Magnetic Stimulation
• Chapter 42. Stem Cell and Gene Therapy for Autism Spectrum Disorders
• Chapter 43. Gene Therapy and Molecular Interventions
• Part IV
• Chapter 44. Consortiums
• Chapter 45. Employment and Life Outcomes
• Chapter 46. Autism Strengths and Neurodiversity
• Chapter 47. Role of Patient Advocacy Groups in Treatment Development

More than 40 years after the official recognition of infantile autism in DSM-III, advances continue to be made in our understanding of the possible causes, assessment and evaluation, and treatment of autism spectrum disorder (ASD). With contributions by dozens of experts in the field, this second edition of the Textbook of Autism Spectrum Disorders has been updated to reflect the latest research in ASD. Unrivaled in its thoroughness, this volume discusses issues of assessment and evaluation; examines the etiology of ASD and its recognized associations with other medical conditions; analyzes standard and experimental treatments; and delves into social policy issues pertinent to individuals with ASD and those who treat them. With summary points in each chapter and copious lists of recommended readings, this is an indispensable resource for psychiatrists, psychologists, neurologists, social workers, speech therapists, educators, and all others in the continuum of care.